Objectives This study aims to report tumor control rates and cranial nerve function after low dose (11.0 Gy) Gamma knife radiosurgery (GKRS) in patients with vestibular schwannomas. Methods A retrospective chart review was performed on 30 consecutive patients with vestibular schwannomas treated from March 2004 to August 2010 with GKRS at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The marginal dose for all patients was 11.0 Gy prescribed to the 50% isodose line. Median follow-up time was 42 months. The median treatment volume was 0.53 cm 3 . Hearing data were obtained from audiometry reports before and after radiosurgery. Results The actuarial progression free survival (PFS) based on freedom from surgery was 100% at 5 years. PFS based on freedom from persistent growth was 91% at 5 years. One patient experienced tumor progression requiring resection at 87 months. Serviceable hearing, defined as Gardner-Robertson score of I-II, was preserved in 50% of patients. On univariate and multivariate analyses, only higher mean and maximum dose to the cochlea significantly decreased the proportion of patients with serviceable hearing. Conclusion Vestibular schwannomas can be treated with low doses (11.0 Gy) of GKRS with good tumor control and cranial nerve preservation.
Introduction
Vestibular schwannomas are cranial nerve sheath tumors that arise from the vestibular branch of the eighth cranial nerve in the internal acoustic meatus, the cerebellopontine angle, or both. 1 The incidence is approximately 0.6 per 100,000 person years and they represent about 6% of intracranial tumors. 2 While these tumors are benign and usually slow growing, they can eventually cause a range of symptoms including hearing loss, tinnitus, vertigo, and facial nerve dysfunction. One option for patients with tumors < 1.5 cm in diameter that are relatively asymptomatic is observation with serial hearing tests and magnetic resonance imaging (MRI) scans. 3 Alternatively, tumors can be treated with microsurgery or radiation therapy with photons or protons. Progression rates following stereotactic radiosurgery (SRS) are similar to recurrence and progression rates seen following surgery and fractionated radiotherapy respectively. [4] [5] [6] [7] [8] [9] Progressive tumors are treated with either microsurgery or radiosurgery.
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Tumors < 3cm in diameter can be treated initially with single fraction SRS (range, 12-16 Gy), fractionated radiation therapy (range, 50-54 Gy) or proton therapy. 10 There are no direct comparisons among these modalities and outcomes with respect to tumor control and hearing preservation have been similar. [9] [10] [11] Tumor control rates following SRS, defined as freedom from surgery, range from 91 to 95% over 3 years, and hearing preservation rates range from 25 to 78%. Currently, most Gamma knife (Elekta Instrument AB Stockholm, Sweden) centers treating vestibular chwannomas prescribe doses of 12 to 13 Gy to the 50% isodose line. Given the good clinical results following all of the therapeutic options described above, many centers treating this benign tumor have attempted to reduce prescribed radiation doses to limit treatmentrelated hearing loss and other cranial nerve complications. 1, 4, 7, [12] [13] [14] [15] [16] The Thomas Jefferson group has shown that tumor control rates and cranial nerve preservation were excellent following a lower dose of 46.8 Gy compared with 50. 4 Gy delivered with a fractionated stereotactic radiation therapy technique. 11 In a similar attempt, we have treated all vestibular schwannoma patients at our center with Gamma knife radiosurgery (GKRS) to 11.0 Gy prescribed to the 50% isodose line. Prescription to the 50% isodose line is typical of GKRS and, compared with typical linear accelerator-based SRS, results in higher doses within the tumor itself. Any difference in tumor dose between GKRS and what might be delivered with linear acceleratorbased SRS is an incidental result of these differences in prescription to the tumor periphery. Given the unique dosimetric advantages of GKRS, by prescribing to a lower isodose line (50%) compared with linear accelerator-based SRS, we were hopeful that the resultant dose escalation within the target volume would compensate for any reduction in therapeutic effect that might be caused by reduction in prescribed dose from 12 to 13 to 11 Gy. This study reports the tumor control rates and cranial nerve function preservation rates in these patients.
Methods
Between March 2004 and August 2011, 30 consecutive patients were treated with GKRS for vestibular schwannoma at the Robert H. Lurie Cancer Center of Northwestern University. None of the patients had previously undergone treatment. Patient and treatment outcome data were collected retrospectively from patient charts and were recorded with respect to age, sex, previous intervention, MRI dates, initial tumor volume and diameter, margin dose, tumor growth, need for resection subsequent intervention, audiometry data, and NF2 status.
Radiosurgery Technique
SRS was performed using Model 4-C or Perfexion Leksell Gamma knife (Elekta Instrument AB Stockholm). After stereotactic frame application, target delineation was performed using high-resolution contrast-enhanced MRI. The GKRS plan was performed using multiple isocenters to deliver conformal radiation treatment. The GKRS plan was jointly reviewed by a neurosurgeon, radiation oncologist, and medical physicist. The doses to the brainstem and the cochlea were evaluated. The median tumor volume was 0.53 cm 3 (range, 0.025-4.7 cm 3 ). The marginal dose for all patients was 11.0 Gy prescribed to the 50% isodose line. Multiple isocenters (range: 1-17, median: 7) were used to deliver conformal radiosurgery. The cochlear dose depends on the lateral extent of the tumor and also on the size and number of shots used for treatment planning. For acoustic neuromas we only use 4 and 8 mm shots and we used blocking to reduce the cochlear dose. Patient records were examined for evidence of cranial neuropathies and complications from GKRS based on evaluations of the treating physician.
Follow-Up
Follow-up time was calculated from the date of GKRS to the most recent MRI or otolaryngology (ENT) visit, whichever was later. Clinical and MRI follow-up was performed at 3 months, then every 6 months for the first 2 years, and annually thereafter.
Tumor Progression
Progression free survival (PFS) was defined as: (1) freedom from repeat surgical intervention and (2) freedom from persistent tumor growth after radiosurgery. 13, 17 Tumor size was calculated assuming spherical dimensions as length Â width Â height Â 0.52.
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Hearing Preservation
Audiometry results were reviewed each of the patients treated at Northwestern, and audiometry results pre-and postradiosurgery were available for 18 of 30 patients. Pure tone audiometry decibel levels, speech recognition threshold (SRT), and word recognition score (WRS) were tabulated. The Gardner-Robertson (GR) score 20 was calculated from SRT and WRS to obtain an assessment of overall hearing because this is the standard used in studies of hearing in vestibular schwannomas. Serviceable hearing was defined as a GR score of I-II, which is based on both SRT 50 dB and WRS ! 50%. If the WRS and SRT did not lead to the same categorization, the higher (worse hearing) GR score was used. The serviceable hearing preservation rate was defined as the percentage of patients who maintained serviceable hearing at follow-up. The GR score preservation rate was defined as the percentage of patients that maintained the same GR at follow-up. Tinnitus is a quality of life issue for patients, however, it is a subjective measure of hearing. Given the limitations of collecting subjective information in a retrospective study, we decided to limit our discussion of hearing toxicity to the results from formal hearing tests.
Facial Nerve Function
Facial nerve damage before and after treatment was evaluated based on the examining physician's determination of the presence or absence of facial nerve deficit. Facial nerve function was measured using the House-Brackmann index (HB). 21 Values, where possible, were based either on reported HB index, or estimated retrospectively based on charted physical examination findings of facial nerve dysfunction. Consistent with prior studies, facial nerve dysfunction following GKRS was defined as facial nerve functioning HB score III or greater in patients who had HB score of I-II before GKRS. 4 An estimate of the House-Brackmann index was calculated based on charted physical examination finding.
The rate of new facial nerve dysfunction was calculated as the percentage of patients with new facial nerve dysfunction or worsening of the HB index at follow-up.
Trigeminal Neuropathy
Trigeminal neuropathy was defined as new facial numbness or trigeminal neuralgia as reported in the patient chart. It was recorded as either present or absent. The rate of new trigeminal neuropathy was calculated as the percentage of patients with trigeminal neuropathy at follow-up.
Vestibular Nerve Dysfunction
Vestibular nerve dysfunction was assessed by the presence or absence of balance difficulty before and after treatment as noted in the patient examination records. The vestibular nerve dysfunction was new if it was reported after but not before GKRS, and it was reported as worse if the patient record explicitly stated that the functioning was worse after GKRS. Results of vestibular nerve dysfunction are reported as the composite of new or worse vertigo or unsteadiness following GKRS.
Statistical Analysis
The clinical data were tabulated using Microsoft Excel (Excel 14.2.3, Microsoft Corporation, Redmond, Washington). Statistical analysis, correlation analysis, multivariate analysis, and Kaplan-Meier survival curves were computed using GraphPad Prism (GraphPad Software, Inc., San Diego, California) and R (R Foundation for statistical computing, Vienna, Austria). Using the Clopper-Pearson interval 95% confidence intervals (CI) were calculated with R. Survival curves were compared using the log-rank test for significance. Statistical significance was set arbitrarily at p < 0.05. Univariate and multivariate analyses were performed using a Cox proportional hazards model. In addition, Fisher exact test with a two-tailed p value was used to compare hearing outcomes for mean cochlear doses above or below 12 Gy and for max cochlear doses above or below 6 Gy. The Institutional Review Board at the Lurie Comprehensive Cancer Center of Northwestern University approved of data collection, analysis, and publication of this study, and the study was performed within ethical standards. The KaplanMeier survival method was used to calculate PFS based on freedom from repeat intervention. Survival proportions were calculated using the Kaplan and Meier method in GraphPad prism. When survival proportions were 100%, confidence intervals were calculated using the Wald method based on the number of patients at risk. Patient characteristics are tabulated in ►Table 1.
Results
No complications such as hydrocephalus, radionecrosis, or tumor cystic cavitation were noted in any patient. One patient (3.3%) had a complication of vestibular neuritis (new dizziness) following GKRS and was treated with steroids. There were no treatment-related deaths. Other treatment-related side effects are outlined below.
Facial Neuropathy
Out of 30 patients, 2 (7%) patients had some facial nerve dysfunction before GKRS (HB of 3 or more). Zero percent of patients with normal (HB 1-2) facial nerve functioning before GKRS had new or worse facial nerve dysfunction (HB 3 or more) after GKRS. Results are summarized in ►Table 2. 
Dosimetry
The dose for all patients was 11.0 Gy prescribed to the 50% isodose line. The average cochlear volume was 0.068 cm 3 (range, 0.016-0.128 cm 3 ). The average minimum cochlear 
Hearing Preservation
A total of 18 patients had audiometry data available before and after GKRS. Out of these, 61% patients had serviceable hearing before GKRS and 33% of all patients had serviceable hearing after GKRS. Of the 11 patients with serviceable hearing before GKRS, 55% maintained serviceable after GKRS (►Fig. 1D). Of the 18 patients with some level of speech discrimination before GKRS (GR I-IV), 100% maintained a GR of at least IV. Around 6% (1/18) of patients showed an improvement in GR score. Results are shown in ►Table 4. Serviceable hearing was preserved in 100 versus 13% of patients receiving a mean dose to the cochlea of less than 6 versus 6 Gy or more, respectively (p ¼ 0.005, n ¼ 13). Among patients with preserved serviceable hearing, half received a mean cochlear dose of < 4 Gy and half received a mean cochlear dose of 4 to 10 Gy. GR score was maintained in 100 versus 18% of patients receiving a mean dose to the cochlea of less than 6 versus 6 Gy or more, respectively (p ¼ 0.001, n ¼ 19). Results are shown in ►Table 5. Serviceable hearing was preserved in 80 versus 25% of patients receiving a maximum dose to the cochlea of less than 12 versus 12 Gy or more, respectively (p ¼ 0.10, n ¼ 13). Among patients who had preserved serviceable hearing, two-thirds received a maximum cochlear dose of < 10 Gy. All patients who did not have preserved serviceable hearing had received a maximum cochlear dose of > 11 Gy. GR score was maintained in 89 versus 20% of patients receiving a maximum dose to the cochlea of less than 12 versus 12 Gy or more, respectively (p ¼ 0.01, n ¼ 19). Results are shown in ►Table 6.
Univariate and Multivariate Analyses
Univariate and multivariate analyses were performed using a Cox proportional hazards model. Three independent variables were modeled: tumor progression, tumor expansion, and hearing preservation. Each of these independent variables was modeled with respect to age and tumor volume. Hearing preservation was further modeled with respect to transient tumor expansion and mean cochlear dose. A similar analysis was done on hearing preservation with maximum cochlear dose instead of mean cochlear dose. Dose was not modeled as an independent variable because it was uniform throughout the study population. There were no significant correlations in any of the three models with respect to age, tumor volume, or transient tumor expansion (p > 0.05). However, on univariate and multivariate analyses, mean and maximum cochlear dose had a statistically significant detrimental impact on hearing preservation. The results from these analyses are shown in ►Tables 7 and 8.
Discussion
In the past two decades, SRS for vestibular schwannomas has gained favor over microsurgery because of its improved side effect profile and similar rate of tumor control. 1, 16, 18 There are no randomized trials comparing the two techniques, however, and efficacy data relies on retrospective studies. Based on these data, SRS is now widely considered a viable alternative to microsurgery for the treatment of vestibular schwannomas, 1, 5, 22 and surgery is still used for tumors > 3 cm in diameter. Another review by Yang et al showed the combined results of 5,825 patients treated for vestibular schwannoma with SRS. 24 The mean tumor control rate in that review was 94%
after a median follow-up time of 34 months, and the mean dose was 16 Gy. For patients treated with 12.5 Gy, the mean tumor control rates were 94 AE 3% after a median follow-up time of 34 months. Other studies report a tumor control of 91 to 95% over 3 years. [4] [5] [6] [7] [8] There have been multiple small studies reporting favorable outcomes for patients treated with 12 Gy or less. Aiba and coworkers treated 25 patients to a median of 12 Gy (range, 11-14 Gy) and found a PFS based on freedom from surgery of 100% at 45 months.
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Later, Uyama and coworkers reported the results of 51 patients also treated at Osaka City General Hospital to a median of 12 Gy (range, 8-12 Gy). These results included six patients treated to 11 Gy or less, with two treated to 8 Gy, and four treated to 10 Gy. 28 Patients with larger tumors were treated with lower doses to the tumor margin. Overall, the PFS based on freedom from surgery was 96% at a median of 60 months. Separate results were not reported for the tumors treated to 11 Gy or less, although one of the two retreated tumors was initially treated with 12 Gy. Régis et al at Hôpital de la Timone in Marseille reported results of 3,050 patients treated from 1992 to 2011 of whom 2,336 had follow-up of 3 years or more. The mean dose was 12.3 Gy. The authors reported that all patients with serviceable hearing (GR I-II) were treated with 11 Gy, and 46% of the patients in this series had serviceable hearing. However, results were not reported separately for patients receiving 11 Gy. The tumor control rate was 97.5% at 3 years. 29 Petit et al at the University of Maryland treated 47 patients with a median of 12 Gy (range, 10-15 Gy) and the actuarial PFS based on freedom from surgery was 96% (range, 92-100%) after a median of 43 months. 30 Inoue treated 20 patients to a median of 12 Gy (range, 10-12 Gy) including 4 patients to 10 Gy and 2 patients to 11 Gy. 31 The PFS based on freedom from surgery was 95% at 60 months. Based on the earlier data from Osaka City Hospital and the University of Maryland, and in an attempt to reduce morbidity from treatment for Vestibular Schwannoma (VS), patients at Northwestern were treated with lower doses of 11 Gy. Our results of 5-year PFS of 100 and 91% freedom from persistent tumor growth are comparable with results from prior studies of patients treated with lower dose SRS as summarized above.
Hearing Preservation
Hearing preservation rates, defined as preservation of serviceable hearing scores of I-II using the GR scale, 20 range from 35 to 78% in other studies. ) or by age (< 65 or > 65 years old). In this study, 55% maintained serviceable hearing, comparable to prior reports of 51% in a large review study. 8 Direct comparisons between this and other studies on the effect of dose on hearing preservation are not possible due to the retrospective study design. Several factors have been associated with worse hearing including dose, tumor size, and dose to the cochlea, all of which are associated with total dose. 8, 16, 33 These data, along with other studies and within the limits of study design, support using lower doses to preserve hearing.
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Prior studies have variably demonstrated a link between hearing preservation and factors including dose, tumor volume expansion, and age. 8, [33] [34] [35] [36] [37] Univariate and multivariate analysis were performed for the patients in our study. However, no correlation for PFS or hearing preservation with respect to age or tumor volume was found. This may be due to the small sample size, and the occurrence of only one patient requiring further intervention after tumor progression.
Other studies have proposed minimizing dose to the cochlea to reduce hearing loss. Results from such studies have shown variable results. 33, 35 Tamura et al at Hôpital de la Timone found that, among patients with GR score of I before treatment, a dose to the cochlea of < 4 Gy was associated (99.5 vs. 95.5%), and doses 13 Gy (98.5 vs. 94.7%). In this report only one (3.3%) of our patients had cranial nerve VII neuropathy after GKRS, compared with 0.5 to 17% in past studies. 4, 13, 22, 29, 38 The rate of cranial neuropathies in our study is on the lower end of past reported figures for patients treated with lower dose SRS.
Summary and Study Limitations
We have given 11 Gy to all patients and continue to do so. The objective was to reduce the dose to the adjacent normal tissues including the cochlea and the fifth cranial nerve and reduce treatment-related side effects. Unlike the series by Régis et al we did not choose this dose based on hearing status but rather to see if we could further reduce the dose safely without compromising tumor control rates. This report is our review of the tumor control rates in a cohort of patients consecutively treated with 11 Gy. We concede that most centers continue to deliver 12 to 12.5 Gy for acoustic neuromas treated with GKRS. Our study, despite the limitations of a small number of patients and a relatively short follow-up after radiosurgery, compares favorably to other published reports on low doses of SRS and has demonstrated excellent tumor control rates and good cranial nerve function preservation. Furthermore, we have shown that reducing mean and maximum cochlear dose can result in higher hearing preservation rates. More clinical data and longer follow-up are required to confirm that good cranial nerve function preservation and tumor control can be maintained after treatment with lower doses of GKRS.
Conclusion
This report demonstrates that low-dose GKRS (11 Gy) for vestibular schwannomas can result in similar tumor control rates and cranial nerve function preservation compared with higher dose radiosurgery. Furthermore, we have shown that reductions in cochlear dose can lead to improved hearing preservation rates. Further studies are required to confirm long-term maintenance of tumor control and cranial nerve function in these patients.
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